Cannabinoids and COVID-19

Overview

Journal Med Cannabis Cannabinoids

Publisher Karger

Date 2021 Oct 21

PMID 34671712

Citations 12

Authors

Myriam El Biali

Barbara Broers

Marie Besson

Jules Demeules

Affiliations

Soon will be listed here.

Abstract

Since the endocannabinoid system is involved in immune function, the effect of cannabinoid intake on infectious conditions is questioned for several years and is of particular interest in the COVID 19 pandemia. Some data suggest that the immunomodulatory effect of cannabinoids may affect the course and severity of SARS-CoV-2 infection. Given the large number of cannabinoids consumers in the community, this commentary presents the current knowledge on the potential impact of cannabinoids and endocannabinoids on bacterial and viral infection courses namely SARS-CoV-2 disease. Practical recommendations, which can be drawn from the literature, are given.

Citing Articles

Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.

Hassan Kalantar Neyestanaki M, Gholizadeh O, Hosseini Tabatabaie F, Akbarzadeh S, Yasamineh S, Afkhami H Virusdisease. 2024; 35(2):342-356.

PMID: 39071880 PMC: 11269557. DOI: 10.1007/s13337-024-00871-0.

Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations.

Holmes J, Islam S, Milligan K Viruses. 2024; 16(6).

PMID: 38932170 PMC: 11209085. DOI: 10.3390/v16060878.

Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review.

Zielinska A, Eder P, Karczewski J, Szalata M, Hryhorowicz S, Wielgus K Front Immunol. 2023; 14:1147991.

PMID: 37033914 PMC: 10073701. DOI: 10.3389/fimmu.2023.1147991.

Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment.

Perez R, Glaser T, Villegas C, Burgos V, Ulrich H, Paz C Life (Basel). 2022; 12(12).

PMID: 36556483 PMC: 9784976. DOI: 10.3390/life12122117.

Comparative study of CNR1 and CNR2 cannabinoid receptors expression levels in COVID-19 patients with and without diabetes mellitus: Recommendations for future research targets.

Aghamahdi F, Shafiee A, Rostami S, Mokhames Z, Safavi M, Yaslianifard S Diabetes Metab Syndr. 2022; 16(5):102499.

PMID: 35580523 PMC: 9078453. DOI: 10.1016/j.dsx.2022.102499.

References

Costiniuk C, Jenabian M . Cannabinoids and inflammation: implications for people living with HIV. AIDS. 2019; 33(15):2273-2288. DOI: 10.1097/QAD.0000000000002345. View

Cabral G, McNerney P, Mishkin E . Delta-9-tetrahydrocannabinol enhances release of herpes simplex virus type 2. J Gen Virol. 1986; 67 ( Pt 9):2017-22. DOI: 10.1099/0022-1317-67-9-2017. View

De Petrocellis L, Ligresti A, Moriello A, Allara M, Bisogno T, Petrosino S . Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2010; 163(7):1479-94. PMC: 3165957. DOI: 10.1111/j.1476-5381.2010.01166.x. View

Nichols J, Kaplan B . Immune Responses Regulated by Cannabidiol. Cannabis Cannabinoid Res. 2020; 5(1):12-31. PMC: 7173676. DOI: 10.1089/can.2018.0073. View

Berlin I, Thomas D, Le Faou A, Cornuz J . COVID-19 and Smoking. Nicotine Tob Res. 2020; 22(9):1650-1652. PMC: 7184428. DOI: 10.1093/ntr/ntaa059. View

Morales P, Hurst D, Reggio P . Molecular Targets of the Phytocannabinoids: A Complex Picture. Prog Chem Org Nat Prod. 2017; 103:103-131. PMC: 5345356. DOI: 10.1007/978-3-319-45541-9_4. View

Mestre L, Inigo P, Mecha M, Correa F, Hernangomez-Herrero M, Loria F . Anandamide inhibits Theiler's virus induced VCAM-1 in brain endothelial cells and reduces leukocyte transmigration in a model of blood brain barrier by activation of CB(1) receptors. J Neuroinflammation. 2011; 8:102. PMC: 3173342. DOI: 10.1186/1742-2094-8-102. View

Gui H, Sun Y, Luo Z, Su D, Dai S, Liu X . Cannabinoid receptor 2 protects against acute experimental sepsis in mice. Mediators Inflamm. 2013; 2013:741303. PMC: 3679685. DOI: 10.1155/2013/741303. View

McPartland J, Duncan M, Di Marzo V, Pertwee R . Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2014; 172(3):737-53. PMC: 4301686. DOI: 10.1111/bph.12944. View

10.

Cabral G, McNerney P, Mishkin E . Effect of micromolar concentrations of delta-9-tetrahydrocannabinol on herpes simplex virus type 2 replication in vitro. J Toxicol Environ Health. 1987; 21(3):277-93. DOI: 10.1080/15287398709531019. View

11.

Cabral G, Mishkin E, Marciano-Cabral F, Coleman P, Harris L, MUNSON A . Effect of delta 9-tetrahydrocannabinol on herpes simplex virus type 2 vaginal infection in the guinea pig. Proc Soc Exp Biol Med. 1986; 182(2):181-6. DOI: 10.3181/00379727-182-42325. View

12.

Javelot H, Llorca P, Drapier D, Fakra E, Hingray C, Meyer G . [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. Encephale. 2020; 46(3S):S14-S34. PMC: 7196532. DOI: 10.1016/j.encep.2020.04.006. View

13.

Hanus L, Meyer S, Munoz E, Taglialatela-Scafati O, Appendino G . Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016; 33(12):1357-1392. DOI: 10.1039/c6np00074f. View

14.

Pisanti S, Malfitano A, Ciaglia E, Lamberti A, Ranieri R, Cuomo G . Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017; 175:133-150. DOI: 10.1016/j.pharmthera.2017.02.041. View

15.

Guo Y, Cao Q, Hong Z, Tan Y, Chen S, Jin H . The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020; 7(1):11. PMC: 7068984. DOI: 10.1186/s40779-020-00240-0. View

16.

Chen C, Zhang X, Ju Z, He W . [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019]. Zhonghua Shao Shang Za Zhi. 2020; 36(6):471-475. DOI: 10.3760/cma.j.cn501120-20200224-00088. View

17.

Dos Santos R, Guimaraes F, Crippa J, Hallak J, Rossi G, Rocha J . Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin Drug Metab Toxicol. 2020; 16(6):517-526. DOI: 10.1080/17425255.2020.1754793. View

18.

Tahamtan A, Samieipoor Y, Nayeri F, Rahbarimanesh A, Izadi A, Rashidi-Nezhad A . Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice. Virulence. 2017; 9(1):217-230. PMC: 5955186. DOI: 10.1080/21505594.2017.1389369. View

19.

Laprairie R, Bagher A, Kelly M, Denovan-Wright E . Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015; 172(20):4790-805. PMC: 4621983. DOI: 10.1111/bph.13250. View

20.

Thiele E, Marsh E, French J, Mazurkiewicz-Beldzinska M, Benbadis S, Joshi C . Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018; 391(10125):1085-1096. DOI: 10.1016/S0140-6736(18)30136-3. View